Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects

Clinical Pharmacokinetics

Volumn 47, Issue 1, 2008, Pages 61-74

  Darwish, Mona ^a   Kirby, Mary ^a   Robertson Jr , Philmore ^a   Hellriegel, Edward T ^a  

^a CEPHALON INC   (United States)

Author keywords

Armodafinil, drug interactions; Caffeine, drug interactions; Central nervous system stimulants, drug interactions; Cytochrome P450; Drug interactions; Midazolam, drug interactions; Omeprazole, drug interactions; Research and development

Indexed keywords

ARMODAFINIL; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; MIDAZOLAM; OMEPRAZOLE;

ABNORMAL DREAMING; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPERACTIVITY; INSOMNIA; LOOSE FECES; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SOMNOLENCE; TREMOR;

EID: 37149002067     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847010-00006     Document Type: Article

References (22)

1. Robertson Jr P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42 (2): 123-37
2. Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999 Mar; 39 (3): 281-8
3. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 Jan; 39 (1): 30-40
4. Roth T, Czeisler CA, Walsh JK, et al. Randomized, double-blind, placebo-controlled study of armodafinil for the treatment of excessive sleepiness associated with chronic shift work sleep disorder [abstract 161]. Neuropsychopharmacology 2005; 30: S140
5. Hirshkowitz M, Black JE, Wesnes K, et al. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir Med 2007 Mar; 101 (3): 616-27
6. Roth T, White D, Schmidt-Nowara W, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Clin Ther 2006; 28 (5): 689-706
7. Harsh J, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 2006; 22 (4): 761-74
8. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005 Aug 4; 353 (5): 476-86
9. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/ hypopnea syndrome. Sleep 2005 Apr 1; 28 (4): 464-71
10. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001 Nov 1; 164 (9): 1675-81
11. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of moda-finil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998 Jan; 43 (1): 88-97
12. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000 Mar 14; 54 (5): 1166-75
13. Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006 Jan; 22 (1): 159-67
14. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996; 32 (4): 327-37
15. Robertson Jr P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000 Jun; 28 (6): 664-71
16. Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002; 71: 46-56
17. Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002; 42: 205-14
18. US FDA Center for Drug Evaluation and Research. Guidance for industry: E6 good clinical practice: consolidated guidance [online]. Rockville (MD): US FDA, 1996. Available from URL: http://www.fda.gov/cder/guidance/959fnl.pdf [Accessed 2007 Nov 7]
19. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995 Jun; 57 (6): 662-9
20. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987 Dec; 15 (6): 657-80
21. Snedecor G, Cochran W. Statistical methods. 8th ed. Ames (IA): Iowa State University Press, 1989
22. Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996 Mar; 37 (3): 253-7